Author

Ashwin Abhang

Institution: University of Connecticut

Observed institutions: University of Connecticut, Bristol-Myers Squibb (India), National Institute of Pharmaceutical Education and Research

ORCID: 0009-0007-9713-6340

Observed ORCID: 0009-0007-9713-6340

OpenAlex ID: A5092006937

Peptide–Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical Progress

2025 · Krishna Jadhav, Ashwin Abhang, et al. · Bioengineering · 52

Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management

2023 · Ashwin Abhang, Oly Katari, et al. · Drug Delivery and Translational Research · 21

Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer

2024 · Eknath Kole, Krishna Jadhav, et al. · Current Drug Delivery · 17

Revealing the potential of nano spray drying for effective delivery of pharmaceuticals and biologicals

2024 · Krishna Jadhav, Eknath Kole, et al. · Drying Technology · 15

In vitro-in vivo relationship and microstructural insights into long-acting levonorgestrel intrauterine systems

2025 · Suraj Fanse, Andrew Clark, et al. · Journal of Controlled Release · 8

Recent advancements and future applications of intrauterine drug delivery systems

2025 · Ashwin Abhang, Diane J. Burgess · Expert Opinion on Drug Delivery · 5

Works count: 6

Citation count: 118

H-index: 5

I10-index: 4